3-Methoxybenzamide (3MB) is one of a series of chemical inhibitors of the nuclear enzyme adenosine diphosphate (ADP)-ribosyl transferase (ADPRT), which has been shown to inhibit cell differentiation in vitro, but has no effect on differentiation independent proliferation. Treatment of mice with an optimal concentration of 3MB (20 mg/kg body weight) at or 1 day after dinitrophenyl-keyhole limpet haemocyanin (DNP-KLH) immunisation reduced anti-DNP plaque-forming cell (PFC) numbers to less than 10% of those of control animals. The period for maximum PFC suppression showed a narrow time window relative to immunisation, suggesting that in vivo, as in vitro, 3MB was acting only on those lymphocytes differentiating in response to antigen. Experimental findings showed that it was possible to select for PFC derived from different populations of DNP-responsive lymphocytes by adjusting the time of 3MB treatment relative to immunisation. When 3MB was used with antigen priming, the residual PFC showed a lower average affinity than PFC in mice treated with 3MB 3 days after priming, suggesting a differential selection of those lymphocytes responding either ‘early’ or ‘late’ in the primary immune response.

This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.